nicotine has been researched along with citalopram in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.00) | 18.2507 |
| 2000's | 16 (53.33) | 29.6817 |
| 2010's | 8 (26.67) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Engberg, G | 1 |
| Clarke, PB; Reuben, M | 1 |
| Engel, JA; Olausson, P; Söderpalm, B | 1 |
| Kozela, E; Krawczyk, M; Popik, P | 1 |
| Chait, A; de Beaurepaire, R; Molimard, R; Rat, P; Touiki, K | 2 |
| Ma, Z; McCarley, RW; McKenna, JT; Strecker, RE; Tao, R; Thakkar, MM | 1 |
| Arib, O; Chait, A; de Beaurepaire, R; Molimard, R; Rat, P; Touiki, K | 1 |
| Andreasen, JT; Redrobe, JP | 1 |
| Bourke, J; Roper, S | 1 |
| Bevins, RA; Dion, AM; Murrin, LC; Sanderson, SC | 1 |
| Gruca, P; Lason-Tyburkiewicz, M; Litwa, E; Papp, M; Willner, P | 1 |
| Cray, J; Durham, E; Howie, RN; Larson, N; LaRue, A | 1 |
| Foster Olive, M; Gipson, CD; Leyrer-Jackson, JM; McCallum, J; Piña, JA | 1 |
| López de Alda, M; López-García, E; López-Martínez, J; Moreno-Merino, L; Postigo, C | 1 |
| Khakpai, F; Zarrindast, MR | 1 |
30 other study(ies) available for nicotine and citalopram
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Citalopram and 8-OH-DPAT attenuate nicotine-induced excitation of central noradrenaline neurons.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amino Acids; Animals; Citalopram; Injections, Intravenous; Locus Coeruleus; Male; Neurons; Nicotine; Norepinephrine; Rats; Rats, Sprague-Dawley; Serotonin | 1992 |
Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release.
Topics: Acetylcholine; Alkaloids; Animals; Azocines; Bacterial Toxins; Citalopram; Corpus Striatum; Cyanobacteria Toxins; Hippocampus; In Vitro Techniques; Male; Marine Toxins; Microcystins; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Norepinephrine; Potassium; Quinolizines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Serotonin Antagonists; Synaptosomes; Tetrodotoxin; Tritium; Tropanes | 1996 |
Behavioral sensitization to nicotine is associated with behavioral disinhibition; counteraction by citalopram.
Topics: Animals; Citalopram; Drug Interactions; Male; Maze Learning; Motor Activity; Nicotine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 1999 |
Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram.
Topics: Animals; Antidepressive Agents; Citalopram; Drug Synergism; Hindlimb Suspension; Imipramine; Immobilization; Locomotion; Male; Mice; Mice, Inbred C57BL; Nicotine; Nicotinic Antagonists; Receptors, Nicotinic | 2003 |
Harmane inhibits serotonergic dorsal raphe neurons in the rat.
Topics: Action Potentials; Analysis of Variance; Animals; Carbolines; Citalopram; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Harmine; Male; Neurons; Neurotoxins; Nicotine; Nicotinic Agonists; Oxazoles; Phenethylamines; Piperazines; Pyridines; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin; Serotonin Antagonists | 2005 |
Effects on serotonin of (-)nicotine and dimethylphenylpiperazinium in the dorsal raphe and nucleus accumbens of freely behaving rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Carrier Proteins; Citalopram; Dimethylphenylpiperazinium Iodide; Male; Microdialysis; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Nucleus Accumbens; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Receptors, Presynaptic; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Receptor Agonists | 2005 |
Effects of tobacco and cigarette smoke extracts on serotonergic raphe neurons in the rat.
Topics: Anabasine; Animals; Citalopram; Data Interpretation, Statistical; Electrophysiology; Male; Neurons; Nicotiana; Nicotine; Plant Extracts; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Smoke | 2007 |
Chronic intermittent nicotine treatment dose-dependently alters serotonergic neurons response to citalopram in the rat.
Topics: Animals; Citalopram; Dose-Response Relationship, Drug; Nicotine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin | 2008 |
Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depressive Disorder; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Mecamylamine; Mice; Morpholines; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Norepinephrine; Reboxetine; Receptors, Nicotinic; Selective Serotonin Reuptake Inhibitors; Serotonin | 2009 |
In with the new: the determinants of prescribing innovation by general practitioners in Ireland.
Topics: Age Factors; Androstenes; Citalopram; Drug Prescriptions; Drug Utilization; Ethinyl Estradiol; General Practitioners; Humans; Information Dissemination; Insurance Claim Review; Ireland; Lactones; Loratadine; Nicotine; Omeprazole; Practice Patterns, Physicians'; Residence Characteristics; Sulfones; Therapies, Investigational; Time Factors | 2012 |
Diminished conditioned responding to the nicotine stimulus by antidepressant drugs with differing specificity for the serotonin and norepinephrine transporter.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Discrimination Learning; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Generalization, Response; Imipramine; Male; Morpholines; Nicotine; Nicotinic Agonists; Norepinephrine Plasma Membrane Transport Proteins; Random Allocation; Rats; Rats, Sprague-Dawley; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Tobacco Use Disorder | 2012 |
Effects of chronic mild stress on the development of drug dependence in rats.
Topics: Animals; Chronic Disease; Citalopram; Depressive Disorder; Diazepam; Disease Models, Animal; Flumazenil; GABA Modulators; Male; Mecamylamine; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Stress, Psychological; Substance Withdrawal Syndrome; Substance-Related Disorders | 2014 |
Pharmacological exposures may precipitate craniosynostosis through targeted stem cell depletion.
Topics: Animals; Citalopram; Craniosynostoses; Culture Media; Down-Regulation; Female; Male; Mice; Mice, Inbred C57BL; Nicotine; Selective Serotonin Reuptake Inhibitors; Skull; Stem Cells; Thyroid Hormones; Thyroxine; Zinc Finger Protein GLI1 | 2019 |
Direct administration of ifenprodil and citalopram into the nucleus accumbens inhibits cue-induced nicotine seeking and associated glutamatergic plasticity.
Topics: Animals; Citalopram; Cues; Dendritic Spines; Drug-Seeking Behavior; Excitatory Amino Acid Antagonists; Extinction, Psychological; Glutamic Acid; Male; Neuronal Plasticity; Neurons; Nicotine; Nucleus Accumbens; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Selective Serotonin Reuptake Inhibitors; Self Administration | 2020 |
Human footprint on the water quality from the northern Antarctic Peninsula region.
Topics: Antarctic Regions; Citalopram; Clarithromycin; Environmental Monitoring; Humans; Nicotine; Water Quality | 2023 |
The effect of nicotine on antidepressant and anxiolytic responses induced by citalopram and citicoline in mice.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Citalopram; Cytidine Diphosphate Choline; Maze Learning; Mice; Nicotine | 2023 |